# Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery

> **NCT01159964** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 60 (actual)

## Conditions studied

- Lung Cancer, Non-Small Cell

## Interventions

- **BIOLOGICAL:** Immunotherapeutic GSK2302032A, different formulations

## Key facts

- **NCT ID:** NCT01159964
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07-20
- **Primary completion:** 2011-10-19
- **Final completion:** 2014-09-10
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Study termination due to negative Phase III of another study product from same technology platform.
- **Last updated:** 2018-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01159964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01159964, "Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01159964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*